

14 February 2025

Ecofibre restructures Australian loans

Ecofibre Limited (Ecofibre, Company) (ASX:EOF) today provided a further update on progress in the Company's plan to restructure its balance sheet and deliver more sustainable financial performance.

Following completion of the sale and leaseback of three properties announced on 18 December 2024, and the working capital loans announced on 23 December 2024, the Company has now reached agreement with its two unsecured lenders in Australia to extend the term of their loans.

- **James & Cordelia Thiele Trust Fund:** The existing \$7.0m loan was partially due on 1 January 2025 (\$1.0m) with the balance payable on 15 July 2025.

In January 2025 the Company repaid \$0.5m, and the term of the remaining debt has now been extended as follows:

- New Facility Amount – AUD6.5m
 - Interest Rate – 14%, increased if the RBA cash rate exceeds 5%
 - Principal Payments and Term – \$650,000 due on 1 January 2026; \$750,000 due on 1 January 2027; balance due on 1 January 2028.
- **Lambert Superannuation Fund:** The existing loan was fully repayable on 15 July 2025, and has now been extended as follows:
 - Facility Amount – AUD3.5m
 - Interest Rate – 10%
 - Principal Payments and Term – \$10,000 per month payable April to June 2025 inclusive, and thereafter \$30,000 per month until the loan is repaid.

Investor Relations and Media, please contact:

Level 12, 680 George Street, Sydney NSW 2000
Paul Edwards, investor-relations@ecofibre.com

About Ecofibre

Ecofibre owns a portfolio of high-quality advanced manufacturing and technology businesses in the United States and Australia. We operate three vertically integrated businesses focused on sustainable polymers and natural materials, natural health care, and hemp seed genetics. In addition, we own a majority interest in a life sciences business that is developing treatments for malignant and non-malignant gynaecological conditions.

Ecofibre Advanced Technologies (formerly known as Hemp Black) is an advanced manufacturing business with specialist capabilities in performance yarn extrusion, polymer compounding, and sustainable materials.

Ananda Health is a leading US manufacturer of cannabinoid-based health products for human and pet consumption. Our focus is on providing high-quality, research-backed products in Australia and the USA, targeting conditions including sleep, anxiety, aches and discomfort, and gynaecological conditions. See anadaprofessional.com and myanandawellness.com.

Ecofibre Genetics owns one of the world's largest collections of hemp seed genetics and is a leading supplier of seed genetics to the hemp fibre and grain industry in the US and Australia.

EOF Bio Inc. is a majority-owned, US-based clinical-stage biotechnology company focused on a new generation of patient-centred cannabinoid-based drugs that improve health outcomes and enhance quality of life, starting with women's health and endometriosis. Spun out of Ecofibre in July 2023 it is focused on commercialising an expanding estate of issued patents.

Authorisation

This document is authorised to be given to the Australian Securities Exchange (ASX) by the Board of the Company.